Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of ABBV-1162 in Healthy Subjects
NCT07832708Phase 1Not yet recruiting
- Sponsor
- AbbVie Inc.
- Start
- Nov 2026
- Primary completion
- May 2027
01
Overview
Phase 1, randomised, double-blind trial comparing ABBV-1162 with Placebo (2 arms). Primary endpoints: Number of Participants Experiencing Adverse Events at 31 days, Maximum Plasma Concentration of ABBV-1162 at 3 days and 5 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
ABBV-1162
Beyond the preview
Go deeper on NCT07832708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07832708.